Darexaban 是选择性的、口服具有活力的 Xa 因子 (FXa) 抑制剂，IC50=54.6 nM。它对其他相关丝氨酸蛋白酶（如胰蛋白酶、凝血酶和激肽释放酶）具有高选择性。它具有抗凝和抗血栓形成作用。

Darexaban (Tanexaban, YM-150) is a direct inhibitor of Factor Xa.Darexaban and Darexaban glucuronide selectively and competitively inhibit FXA and inhibit prothrombin activity at the site of blood clot (thrombus) formation. This leads to a reduction in blood clot formation in a dose-dependent manner. Reducing clotting will reduce blockages in blood flow, which may reduce the risk of myocardial infarction, unstable angina, venous thrombosis, and ischemic stroke.

365462-23-3

C27H30N4O4

474.55

Darexaban, Tanexaban;YM 150;YM150

DMSO:245 mg/mL (516.28 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years